Joinn Laboratories(China),Ltd.'s EBIT is $410M, below the sector sector average of $2.5T.
Get informed when a big investor buys or sells
+ FollowAs of Jun 30, 2026
Trailing 12 months ending Jun 30, 2026
The latest EBIT for 603127.SS is $410M as of June 2026. That compares with $360M in the prior-year period — up 13.3% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Joinn Laboratories(China),Ltd.'s historical trend and sector peers before judging valuation or financial health.
Over the past year, 603127.SS's EBIT moved from $360M to $410M — a 13.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Joinn Laboratories(China),Ltd.'s operating scale or balance-sheet position.
Against its sector companies, 603127.SS currently prints $410M for EBIT, while the sector average sits near $2.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Joinn Laboratories(China),Ltd.'s growth, margins, and balance sheet.
A EBIT figure of $410M for 603127.SS is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.
After noting 603127.SS's EBIT ($410M), review year-over-year change from $360M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.